Mirtazapine indications

List of indications
Major depressive disorder Hospitalized depressed patients Major depressive disorder (extended periods)

Major depressive disorder
Mirtazapine tablets USP are indicated for the treatment of major depressive disorder. The efficacy of Mirtazapine in the treatment of major depressive disorder was established in six week controlled trials of outpatients whose diagnoses corresponded most closely to the Diagnostic and Statistical Manual of Mental Disorders - 3rd edition (DSM-III) category of major depressive disorder. A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. Return to top

Hospitalized depressed patients
The effectiveness of Mirtazapine in hospitalized depressed patients has not been adequately studied. Return to top

Major depressive disorder (extended periods)
The efficacy of Mirtazapine in maintaining a response in patients with major depressive disorder for up to 40 weeks following 8 to 12 weeks of initial open-label treatment was demonstrated in a placebo-controlled trial. Nevertheless, the physician who elects to use Mirtazapine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Return to top